

Audit Review Table				
UnitedHealthcare Community Plan, Inc - New Mexico (Org ID: 12829, SubID: 10138, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2016; Date & Timestamp - 6/12/2017 1:19:50 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and				
Adult BMI Assessment (aba)		77.78%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)				
<i>BMI Percentile</i>		61.56%	R	Reportable
<i>Counseling for Nutrition</i>		60.58%	R	Reportable
<i>Counseling for Physical Activity</i>		51.82%	R	Reportable
Childhood Immunization Status (cis)				
<i>DTaP</i>		72.02%	R	Reportable
<i>IPV</i>		84.67%	R	Reportable
<i>MMR</i>		86.62%	R	Reportable
<i>HiB</i>		83.70%	R	Reportable
<i>Hepatitis B</i>		83.70%	R	Reportable
<i>VZV</i>		86.13%	R	Reportable
<i>Pneumococcal Conjugate</i>		75.43%	R	Reportable
<i>Hepatitis A</i>		84.91%	R	Reportable
<i>Rotavirus</i>		70.80%	R	Reportable
<i>Influenza</i>		47.20%	R	Reportable
<i>Combination #2</i>		66.67%	R	Reportable
<i>Combination #3</i>		64.72%	R	Reportable
<i>Combination #4</i>		63.02%	R	Reportable
<i>Combination #5</i>		58.39%	R	Reportable
<i>Combination #6</i>		39.90%	R	Reportable
<i>Combination #7</i>		56.69%	R	Reportable
<i>Combination #8</i>		39.42%	R	Reportable
<i>Combination #9</i>		36.74%	R	Reportable
<i>Combination #10</i>		36.25%	R	Reportable
Immunizations for Adolescents (ima)				
<i>Meningococcal</i>		63.99%	R	Reportable

<i>Tdap</i>		79.32%	R	Reportable
<i>HPV</i>		16.30%	R	Reportable
<i>Combination #1</i>		62.77%	R	Reportable
<i>Combination #2</i>		14.60%	R	Reportable
Lead Screening in Children (lsc)		36.74%	R	Reportable
Breast Cancer Screening (bcs)		44.81%	R	Reportable
Cervical Cancer Screening (ccs)		45.26%	R	Reportable
Chlamydia Screening in Women (chl)				
<i>16-20 Years</i>		41.80%	R	Reportable
<i>21-24 Years</i>		50.73%	R	Reportable
<i>Total</i>		47.97%	R	Reportable
Effectiveness of Care: Respiratory				
Appropriate Testing for Children with Pharyngitis (cwp)	Y	61.89%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)		21.66%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y			
<i>Systemic Corticosteroid</i>		33.81%	R	Reportable
<i>Bronchodilator</i>		46.14%	R	Reportable
Medication Management for People With Asthma (mma)	Y			
<i>5-11 Years: Medication Compliance 50%</i>		48.21%	R	Reportable
<i>5-11 Years: Medication Compliance 75%</i>		25.00%	R	Reportable
<i>12-18 Years: Medication Compliance 50%</i>		45.45%	R	Reportable
<i>12-18 Years: Medication Compliance 75%</i>		21.21%	R	Reportable
<i>19-50 Years: Medication Compliance 50%</i>		64.04%	R	Reportable
<i>19-50 Years: Medication Compliance 75%</i>		39.90%	R	Reportable
<i>51-64 Years: Medication Compliance 50%</i>		74.50%	R	Reportable
<i>51-64 Years: Medication Compliance 75%</i>		53.69%	R	Reportable
<i>Total: Medication Compliance 50%</i>		64.17%	R	Reportable
<i>Total: Medication Compliance 75%</i>		41.27%	R	Reportable
Asthma Medication Ratio (amr)	Y			
<i>5-11 Years</i>		70.00%	R	Reportable
<i>12-18 Years</i>		56.10%	R	Reportable

19-50 Years		44.65%	R	Reportable
51-64 Years		52.02%	R	Reportable
Total		50.31%	R	Reportable
Effectiveness of Care: Cardiovascular				
Controlling High Blood Pressure (cbp)		54.99%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	61.54%	R	Reportable
Statin Therapy for Patients With Cardiovascular Disease (spc)	Y			
Received Statin Therapy: 21-75 Years (Male)		62.15%	R	Reportable
Statin Adherence 80%: 21-75 Years (Male)		57.27%	R	Reportable
Received Statin Therapy: 40-75 Years (Female)		47.22%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		57.44%	R	Reportable
Received Statin Therapy: Total		54.11%	R	Reportable
Statin Adherence 80%: Total		57.35%	R	Reportable
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
Hemoglobin A1c (HbA1c) Testing		81.02%	R	Reportable
HbA1c Poor Control (>9.0%)		47.93%	R	Reportable
HbA1c Control (<8.0%)		43.80%	R	Reportable
HbA1c Control (<7.0%)			NR	Not Reported
Eye Exam (Retinal) Performed		60.58%	R	Reportable
Medical Attention for Nephropathy		91.48%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		57.42%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y			
Received Statin Therapy		42.51%	R	Reportable
Statin Adherence 80%		54.33%	R	Reportable
Effectiveness of Care: Musculoskeletal				
Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	52.15%	R	Reportable
Effectiveness of Care: Behavioral				
Antidepressant Medication Management (amm)	Y			
Effective Acute Phase Treatment		53.16%	R	Reportable
Effective Continuation Phase Treatment		38.97%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y			

<i>Initiation Phase</i>		46.15%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>		55.17%	NA	Small Denominator
Follow-Up After Hospitalization for Mental Illness (fuh)	Y			
<i>30-Day Follow-Up</i>		74.61%	R	Reportable
<i>7-Day Follow-Up</i>		57.94%	R	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Y			
<i>30-Day Follow-Up</i>			NR	Not Reported
<i>7-Day Follow-Up</i>			NR	Not Reported
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence (fua)	Y			
<i>30-Day Follow-Up: 13-17 Years</i>			NR	Not Reported
<i>7-Day Follow-Up: 13-17 Years</i>			NR	Not Reported
<i>30-Day Follow-Up: 18+ Years</i>			NR	Not Reported
<i>7-Day Follow-Up: 18+ Years</i>			NR	Not Reported
<i>30-Day Follow-Up: Total</i>			NR	Not Reported
<i>7-Day Follow-Up: Total</i>			NR	Not Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	78.15%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)		56.96%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)		65.00%	NA	Small Denominator
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	57.79%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y			
<i>1-5 Years</i>		33.33%	NA	Small Denominator
<i>6-11 Years</i>		30.30%	R	Reportable
<i>12-17 Years</i>		26.19%	R	Reportable

<i>Total</i>		27.50%	R	Reportable
Effectiveness of Care: Medication				
Annual Monitoring for Patients on Persistent Medications (mpm)	Y			
<i>ACE Inhibitors or ARBs</i>		83.31%	R	Reportable
<i>Digoxin</i>		57.50%	R	Reportable
<i>Diuretics</i>		83.91%	R	Reportable
<i>Total</i>		83.39%	R	Reportable
Effectiveness of Care:				
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)		1.47%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	89.39%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	28.75%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)		64.67%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y			
<i>1-5 Years</i>			NA	Small Denominator
<i>6-11 Years</i>		0.00%	NA	Small Denominator
<i>12-17 Years</i>		6.15%	R	Reportable
<i>Total</i>		4.30%	R	Reportable
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health Services (aap)				
<i>20-44 Years</i>		68.40%	R	Reportable
<i>45-64 Years</i>		82.90%	R	Reportable
<i>65+ Years</i>		98.61%	R	Reportable
<i>Total</i>		78.02%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)				
<i>12-24 Months</i>		93.78%	R	Reportable
<i>25 Months - 6 Years</i>		79.40%	R	Reportable
<i>7-11 Years</i>		82.20%	R	Reportable
<i>12-19 Years</i>		82.47%	R	Reportable

Annual Dental Visit (adv)	Y			
2-3 Years		46.09%	R	Reportable
4-6 Years		59.46%	R	Reportable
7-10 Years		63.23%	R	Reportable
11-14 Years		59.58%	R	Reportable
15-18 Years		48.03%	R	Reportable
19-20 Years		32.33%	R	Reportable
Total		53.93%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y			
Initiation of AOD Treatment: 13-17 Years		50.63%	R	Reportable
Engagement of AOD Treatment: 13-17 Years		16.46%	R	Reportable
Initiation of AOD Treatment: 18+ Years		46.65%	R	Reportable
Engagement of AOD Treatment: 18+ Years		14.87%	R	Reportable
Initiation of AOD Treatment: Total		46.71%	R	Reportable
Engagement of AOD Treatment: Total		14.89%	R	Reportable
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care		74.21%	R	Reportable
Postpartum Care		59.12%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		0.00%	NA	Small Denominator
12-17 Years		59.26%	NA	Small Denominator
Total		42.11%	R	Reportable
Utilization				
Frequency of Ongoing Prenatal Care (fpc)				
<21 Percent		9.98%	R	Reportable
21-40 Percent		9.25%	R	Reportable
41-60 Percent		9.98%	R	Reportable
61-80 Percent		15.82%	R	Reportable
81+ Percent		54.99%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)				
0 Visits		1.70%	R	Reportable
1 Visit		2.92%	R	Reportable
2 Visits		2.43%	R	Reportable

3 Visits		3.16%	R	Reportable
4 Visits		10.46%	R	Reportable
5 Visits		10.46%	R	Reportable
6+ Visits		68.86%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		53.53%	R	Reportable
Adolescent Well-Care Visits (awc)		32.12%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NR	Not Reported
Ambulatory Care: Disabled (ambc)			NR	Not Reported
Ambulatory Care: Other (ambd)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NR	Not Reported
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NR	Not Reported
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N		NR	Not Reported
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N		NR	Not Reported
Identification of Alcohol and Other Drug Services: Other (iadd)	N		NR	Not Reported
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N		NR	Not Reported
Mental Health Utilization: Disabled (mptc)	N		NR	Not Reported
Mental Health Utilization: Other (mptd)	N		NR	Not Reported
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N		NR	Not Reported
Antibiotic Utilization: Disabled (abxc)	N		NR	Not Reported

Antibiotic Utilization: Other (abxd)	N		NR	Not Reported
Standardized Healthcare-Associated Infection Ratio (hai)			R	Reportable
Health Plan Descriptive				
Board Certification (bcr)			R	Reportable
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NR	Not Reported
Enrollment by Product Line: Disabled (enpc)			NR	Not Reported
Enrollment by Product Line: Other (enpd)			NR	Not Reported
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			R	Reportable
Race/Ethnicity Diversity of Membership (rdm)			R	Reportable
Total Membership (tlm)			R	Reportable
Measures Collected using Electronic				
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Inclusion in ECDS: Total</i>			NR	Not Reported
<i>Utilization of PHQ-9: Total</i>			NR	Not Reported
Depression and Remission or Response for Adolescents and Adults (drr)				
<i>EDCS Coverage: Total</i>			NR	Not Reported
<i>Follow-up PHQ-9: Total</i>			NR	Not Reported
<i>Depression Remission: Total</i>			NR	Not Reported
<i>Depression Response: Total</i>			NR	Not Reported